Allogene Therapeutics (ALLO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ALLO Stock Forecast

Allogene Therapeutics stock forecast is as follows: an average price target of $29.00 (represents a 1248.84% upside from ALLO’s last price of $2.15) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

ALLO Price Target

The average price target for Allogene Therapeutics (ALLO) is $29.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $7.00. This represents a potential 1248.84% upside from ALLO's last price of $2.15.

ALLO Analyst Ratings

Buy

According to 8 Wall Street analysts, Allogene Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ALLO stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 0 'Hold' (0.00%), 1 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).

Allogene Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 16, 2024	Debjit Chattopadhyay	H.C. Wainwright	$9.00	$2.98	202.01%	318.60%
May 14, 2024	Kalpit Patel	B.Riley Financial	$7.00	$2.90	141.38%	225.58%
Jun 13, 2022	Jack Allen	Robert W. Baird	$11.00	$9.74	12.94%	411.63%
Jan 03, 2022	Michael Schmidt	Guggenheim	$35.00	$15.29	128.91%	1527.91%
Dec 03, 2021	John Newman	Canaccord Genuity	$55.00	$17.62	212.15%	2458.14%
Oct 08, 2021	Anthony Butler	Roth Capital	$35.00	$13.13	166.57%	1527.91%
Oct 08, 2021	Jason Gerberry	Bank of America Securities	$32.00	$13.13	143.72%	1388.37%
Oct 08, 2021	Mark Breidenbach	Oppenheimer	$40.00	$13.13	204.65%	1760.47%
Oct 08, 2021	Biren Amin	Jefferies	$30.00	$13.13	128.48%	1295.35%
Sep 23, 2021	Dane Leone	Raymond James	$36.00	$27.64	30.25%	1574.42%

Row per page

Go to

The latest Allogene Therapeutics stock forecast, released on May 16, 2024 by Debjit Chattopadhyay from H.C. Wainwright, set a price target of $9.00, which represents a 202.01% increase from the stock price at the time of the forecast ($2.98), and a 318.60% increase from ALLO last price ($2.15).

Allogene Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$8.00
Last Closing Price	$2.15	$2.15	$2.15
Upside/Downside	-100.00%	-100.00%	272.09%

In the current month, the average price target of Allogene Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Allogene Therapeutics's last price of $2.15. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 30, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 09, 2024	Citigroup	Buy	Buy	Hold
Jun 17, 2024	Piper Sandler	Overweight	Overweight	Hold
May 31, 2024	Piper Sandler	Underperform	Underperform	Hold
May 31, 2024	Piper Sandler	-	Overweight	Initialise
May 21, 2024	Oppenheimer	Outperform	Outperform	Hold
May 16, 2024	H.C. Wainwright	Buy	Buy	Hold
May 15, 2024	RBC Capital	Buy	Buy	Hold
Jan 06, 2023	Robert W. Baird	-	Outperform	Upgrade
Dec 13, 2022	Bank of America Securities	-	Reduce	Downgrade

Row per page

Go to

Allogene Therapeutics's last stock rating was published by H.C. Wainwright on Oct 30, 2024. The company gave ALLO a "Buy" rating, the same as its previous rate.

Allogene Therapeutics Financial Forecast

Allogene Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$43.00K	$44.00K	$52.00K	$47.00K	$49.00K	$86.00K	$61.00K	$51.00K	$49.00K	$44.00K	$38.34M
Avg Forecast	-	-	-	-	$8.75K	$7.78K	$7.78K	$7.78K	$15.87K	$10.77K	$2.01M	$11.23K	$22.00K	$14.46K	$13.47K	$8.92K	$7.17K	$12.38K	$8.33K	$-7.69K	$-7.69K	$263.86K	$13.92M	$12.84M
High Forecast	-	-	-	-	$10.34K	$9.19K	$9.19K	$9.19K	$21.16K	$12.73K	$2.01M	$11.35K	$26.00K	$14.69K	$15.91K	$10.54K	$8.47K	$12.38K	$8.33K	$-7.69K	$-7.69K	$263.86K	$13.92M	$15.41M
Low Forecast	-	-	-	-	$7.95K	$7.07K	$7.07K	$7.07K	$13.22K	$9.79K	$2.01M	$11.12K	$17.60K	$14.23K	$12.24K	$8.11K	$6.51K	$12.38K	$8.33K	$-7.69K	$-7.69K	$263.86K	$13.92M	$10.27M
# Analysts	-	-	-	-	4	4	4	6	9	4	7	4	9	4	6	4	3	7	4	3	4	7	4	9
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	2.97%	3.27%	5.83%	6.56%	3.96%	10.32%	-7.93%	-6.63%	0.19%	0.00%	2.99%

Allogene Therapeutics's average Quarter revenue forecast for Dec 23 based on 9 analysts is $22.00K, with a low forecast of $17.60K, and a high forecast of $26.00K. ALLO's average Quarter revenue forecast represents a -48.84% decrease compared to the company's last Quarter revenue of $43.00K (Sep 23).

Allogene Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	4	4	4	6	9	4	7	4	9	4	6	4	3	7	4	3	4	7	4	9
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-62.98M	$-80.52M	$-99.07M	$-96.37M	$-78.63M	$-72.92M	$-76.30M	$-70.63M	$-75.86M	$-68.97M	$-31.10M
Avg Forecast	-	-	-	-	$-1.75K	$-1.55K	$-1.55K	$-1.55K	$-3.17K	$-2.15K	$-402.15K	$-94.71M	$-4.40K	$-2.89K	$-2.69K	$-86.10M	$-72.64M	$-2.48K	$-1.67K	$-78.28M	$1.54K	$-52.77K	$-2.78M	$-40.76M
High Forecast	-	-	-	-	$-1.59K	$-1.41K	$-1.41K	$-1.41K	$-2.64K	$-1.96K	$-402.12K	$-75.77M	$-3.52K	$-2.85K	$-2.45K	$-68.88M	$-58.11M	$-2.48K	$-1.67K	$-62.62M	$1.54K	$-52.77K	$-2.78M	$-32.61M
Low Forecast	-	-	-	-	$-2.07K	$-1.84K	$-1.84K	$-1.84K	$-4.23K	$-2.54K	$-402.17K	$-113.66M	$-5.20K	$-2.94K	$-3.18K	$-103.32M	$-87.17M	$-2.48K	$-1.67K	$-93.93M	$1.54K	$-52.77K	$-2.78M	$-48.92M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	21775.59%	29899.00%	1.15%	1.33%	31756.46%	43768.91%	0.97%	-45920.68%	1437.46%	24.78%	0.76%

undefined analysts predict ALLO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Allogene Therapeutics's previous annual EBITDA (undefined) of $NaN.

Allogene Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	4	4	4	6	9	4	7	4	9	4	6	4	3	7	4	3	4	7	4	9
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-61.31M	$-77.99M	$-98.34M	$-93.32M	$-82.15M	$-74.47M	$-79.71M	$-74.87M	$-78.19M	$-70.94M	$-33.02M
Avg Forecast	$-49.16M	$-51.25M	$-50.21M	$-49.16M	$-68.51M	$-69.35M	$-69.35M	$-67.75M	$-67.24M	$-69.61M	$-73.21M	$-99.95M	$-94.30M	$-108.67M	$-123.18M	$-90.86M	$-77.00M	$-115.22M	$-109.98M	$-82.60M	$-106.24M	$-103.96M	$-87.72M	$-43.28M
High Forecast	$-43.35M	$-45.20M	$-44.27M	$-43.35M	$-60.41M	$-61.16M	$-61.16M	$-51.32M	$-49.44M	$-61.38M	$-64.56M	$-79.96M	$-74.23M	$-95.83M	$-108.62M	$-72.69M	$-61.60M	$-115.22M	$-109.98M	$-66.08M	$-106.24M	$-103.96M	$-87.72M	$-34.62M
Low Forecast	$-60.78M	$-63.37M	$-62.07M	$-60.78M	$-84.70M	$-85.75M	$-85.75M	$-80.06M	$-100.86M	$-86.06M	$-90.51M	$-119.94M	$-120.38M	$-134.36M	$-152.29M	$-109.04M	$-92.40M	$-115.22M	$-109.98M	$-99.12M	$-106.24M	$-103.96M	$-87.72M	$-51.93M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.56%	0.63%	1.08%	1.21%	0.71%	0.68%	0.96%	0.70%	0.75%	0.81%	0.76%

Allogene Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALLO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Allogene Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	4	4	4	6	9	4	7	4	9	4	6	4	3	7	4	3	4	7	4	9
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$17.04M	$18.52M	$18.88M	$21.00M	$18.90M	$19.51M	$19.90M	$19.96M	$19.00M	$18.78M	$16.36M
Avg Forecast	-	-	-	-	$1.90M	$1.69M	$1.69M	$1.69M	$3.44M	$2.34M	$436.22M	$2.44M	$4.77M	$3.14M	$2.92M	$1.93M	$1.55M	$2.69M	$1.81M	$-1.67M	$-1.67M	$57.24M	$3.02B	$2.79B
High Forecast	-	-	-	-	$2.24M	$1.99M	$1.99M	$1.99M	$4.59M	$2.76M	$436.25M	$2.46M	$5.64M	$3.19M	$3.45M	$2.29M	$1.84M	$2.69M	$1.81M	$-1.67M	$-1.67M	$57.24M	$3.02B	$3.34B
Low Forecast	-	-	-	-	$1.73M	$1.53M	$1.53M	$1.53M	$2.87M	$2.12M	$436.19M	$2.41M	$3.82M	$3.09M	$2.66M	$1.76M	$1.41M	$2.69M	$1.81M	$-1.67M	$-1.67M	$57.24M	$3.02B	$2.23B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	5.43%	6.34%	9.76%	13.51%	7.03%	10.79%	-11.92%	-11.96%	0.33%	0.01%	0.01%

Allogene Therapeutics's average Quarter SG&A projection for Dec 23 is $4.77M, based on 9 Wall Street analysts, with a range of $3.82M to $5.64M. The forecast indicates a -71.99% fall compared to ALLO last annual SG&A of $17.04M (Sep 23).

Allogene Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	-	-	-	-	4	4	4	6	9	4	7	4	9	4	6	4	3	7	4	3	4	7	4	9
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.37	$-0.53	$-0.68	$-0.65	$-0.57	$-0.52	$-0.56	$-0.54	$-0.57	$-0.53	$-0.25
Avg Forecast	$-0.23	$-0.24	$-0.24	$-0.23	$-0.33	$-0.33	$-0.33	$-0.32	$-0.32	$-0.33	$-0.35	$-0.41	$-0.45	$-0.52	$-0.59	$-0.62	$-0.64	$-0.61	$-0.58	$-0.60	$-0.56	$-0.55	$-0.46	$-0.57
High Forecast	$-0.21	$-0.22	$-0.21	$-0.21	$-0.29	$-0.29	$-0.29	$-0.25	$-0.24	$-0.29	$-0.31	$-0.36	$-0.35	$-0.46	$-0.52	$-0.54	$-0.57	$-0.61	$-0.58	$-0.60	$-0.56	$-0.55	$-0.46	$-0.57
Low Forecast	$-0.29	$-0.30	$-0.30	$-0.29	$-0.40	$-0.41	$-0.41	$-0.38	$-0.48	$-0.41	$-0.43	$-0.51	$-0.58	$-0.64	$-0.73	$-0.76	$-0.80	$-0.61	$-0.58	$-0.60	$-0.56	$-0.55	$-0.46	$-0.57
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.71%	0.90%	1.10%	1.01%	0.94%	0.90%	0.94%	0.97%	1.04%	1.15%	0.44%

According to undefined Wall Street analysts, Allogene Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALLO previous annual EPS of $NaN (undefined).

Allogene Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ALLO	Allogene Therapeutics	$2.15	$29.00	1248.84%	Buy
IPSC	Century Therapeutics	$1.25	$15.00	1100.00%	Buy
NTLA	Intellia Therapeutics	$14.17	$115.90	717.93%	Buy
SGMO	Sangamo Therapeutics	$1.90	$12.00	531.58%	Buy
HRTX	Heron Therapeutics	$1.17	$7.00	498.29%	Buy
LIFE	aTyr Pharma	$1.90	$11.00	478.95%	Buy
PRME	Prime Medicine	$3.18	$17.25	442.45%	Buy
EDIT	Editas Medicine	$2.52	$12.85	409.92%	Buy
ITOS	iTeos Therapeutics	$7.88	$37.67	378.05%	Buy
VERV	Verve Therapeutics	$4.50	$19.00	322.22%	Buy
RLAY	Relay Therapeutics	$4.89	$19.40	296.73%	Buy
SANA	Sana Bio	$2.34	$8.00	241.88%	Buy
ANNX	Annexon	$5.46	$14.00	156.41%	Buy
BEAM	Beam Therapeutics	$24.12	$58.50	142.54%	Buy
CRBU	Caribou Biosciences	$1.98	$3.00	51.52%	Buy
BPMC	Blueprint Medicines	$90.18	$109.71	21.66%	Buy
VECT	VectivBio	$16.87	$18.00	6.70%	Buy
GTHX	G1 Therapeutics	$7.16	$4.50	-37.15%	Buy

ALLO Forecast FAQ

Is Allogene Therapeutics a good buy?

Yes, according to 8 Wall Street analysts, Allogene Therapeutics (ALLO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of ALLO's total ratings.

What is ALLO's price target?

Allogene Therapeutics (ALLO) average price target is $29 with a range of $7 to $55, implying a 1248.84% from its last price of $2.15. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Allogene Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ALLO stock, the company can go up by 1248.84% (from the last price of $2.15 to the average price target of $29), up by 2458.14% based on the highest stock price target, and up by 225.58% based on the lowest stock price target.

Can Allogene Therapeutics stock reach $3?

ALLO's average twelve months analyst stock price target of $29 supports the claim that Allogene Therapeutics can reach $3 in the near future.

What are Allogene Therapeutics's analysts' financial forecasts?

Allogene Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $32.08K (high $37.92K, low $29.16K), average EBITDA is $-6.414K (high $-5.829K, low $-7.581K), average net income is $-275M (high $-234M, low $-336M), average SG&A $6.96M (high $8.23M, low $6.33M), and average EPS is $-1.314 (high $-1.119, low $-1.607). ALLO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-200M (high $-176M, low $-247M), average SG&A $0 (high $0, low $0), and average EPS is $-0.955 (high $-0.842, low $-1.181).

Did the ALLO's actual financial results beat the analysts' financial forecasts?

Based on Allogene Therapeutics's last annual report (Dec 2023), the company's revenue was $95K, beating the average analysts forecast of $58.85K by 61.44%. Apple's EBITDA was $-328M, beating the average prediction of $-86.113M by 280.59%. The company's net income was $-327M, missing the average estimation of $-417M by -21.52%. Apple's SG&A was $71.67M, beating the average forecast of $12.77M by 461.42%. Lastly, the company's EPS was $-0.0021, missing the average prediction of $-2.176 by -99.90%. In terms of the last quarterly report (Sep 2023), Allogene Therapeutics's revenue was $43K, beating the average analysts' forecast of $14.46K by 197.33%. The company's EBITDA was $-62.975M, beating the average prediction of $-2.892K by 2177458.78%. Allogene Therapeutics's net income was $-61.315M, missing the average estimation of $-109M by -43.58%. The company's SG&A was $17.04M, beating the average forecast of $3.14M by 443.14%. Lastly, the company's EPS was $-0.37, missing the average prediction of $-0.519 by -28.77%